Clinical trials: High-Risk Cancer
Soft Tissue Sarcoma, Lung Metastasis
Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma
Cancer surveillance has a significant cost and generate anxiety for the patient. It is important to avoid exams that will not modify health support or whose results wont allow to decide.
- Trial name
- CASSANDRE (NCT01612481)
- Testing
- chest radiography, chest CT
- Where
- 3 sites in France
- Volunteers
- 11 people
- Sponsor
- Centre Oscar Lambret
Ulcerative Colitis
Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer
The aim of this study is to test Eicosapentaenoic acid's effects on markers relevant to colorectal carcinogenesis, RNA and DNA profiles, and the possibility that Eicosapentaenoic Acid treatment might be associated with changes of…
- Trial name
- EPAUC (NCT02069561)
- Testing
- Eicosapentaenoic Acid
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prostate Cancer
Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services
Earlier work explored barriers and facilitators to accessing prostate cancer screening, particularly in underserved communities, and provided valuable insights to build upon.
- Trial name
- INCLUDE PC (NCT07407686)
- Testing
- Surveys, Semi-structured interviews and focus groups
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Colorectal Cancer, Mismatch Repair-deficient (dMMR)
Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer
This study will evaluate the safety, and tolerability of Cadonilimab as neoadjuvant treatment for resectable local advanced colorectal cancer patient with dMMR/MSI-H.
- Conditions
- Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
- Trial name
- MSI-H/dMMR (NCT05913570)
- Testing
- Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- LiuYing
Neuroblastoma
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
This is a multi-center, single arm trial of two doses of 18 mCi/kg of Ultratrace iobenguane I 131 administered to subjects with high-risk neuroblastoma.
- Trial name
- NCT00992173
- Testing
- Ultratrace Iobenguane I 131
- Where
- 21 sites in United States, Canada
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Neuroblastoma
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and…
- Trial name
- NCT03363373
- Testing
- GM-CSF + Naxitamab
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 122 people
- Sponsor
- Y-mAbs Therapeutics
Breast Cancer, Malignant Neoplasm of Breast
Breast Reconstruction Following Breast Cancer in Very High Risk Patients
The purpose of this study is to: 1. Evaluate whether immediate or delayed reconstruction should be offered for breast reconstruction candidates with higher risk for surgical complications by comparing complications, quality of…
- Trial name
- NCT03261323
- Testing
- Immediate Breast Reconstruction, Delayed Breast Reconstruction, Breast-Q questionnaire
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Myelofibrosis, High-Risk Cancer
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis.
- Conditions
- Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer
- Trial name
- ALLO-BAT (NCT04217356)
- Testing
- Hematopoietic stem cell transplant, Ruxolitinib, Hydroxyurea
- Where
- 5 sites in Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Kidney Cancer
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00087022
- Testing
- girentuximab
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 864 people
- Sponsor
- Heidelberg Pharma AG
Colorectal Cancer
Lifestyle Intervention After Colonoscopy (LIFE-SCREEN Pilot)
The study aims to evaluate the impact of promoting advice on the latest evidence-based diet and lifestyle recommendations for cancer prevention at colorectal cancer (CRC) screening among individuals who may be at higher risk for…
- Trial name
- NCT05273931
- Testing
- Lifestyle intervention
- Where
- 2 sites in France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Centre Leon Berard
Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat…
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT06458439
- Testing
- Epcoritamab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1.
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- Trial name
- NCT06758401
- Testing
- Sigvotatug Vedotin, Pembrolizumab
- Where
- 389 sites in United States, Argentina and 29 more
- Volunteers
- 714 people
- Sponsor
- Pfizer
Multiple Myeloma
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.
- Trial name
- NCT03217812
- Testing
- Velcade, Melphalan, Prednisone
- Where
- 44 sites in China, Hong Kong and 3 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Anaplastic Astrocytoma, Glioblastoma
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations.
- Conditions
- Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
- Trial name
- NCT03581292
- Testing
- Radiation Therapy, Temozolomide, Veliparib
- Where
- 163 sites in United States, Australia and 3 more
- Volunteers
- 38 people
- Sponsor
- Children's Oncology Group
Primary Amyloidosis of Light Chain Type
High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
The aim of the study is to assess survival of patients with advanced cardiac AL amyloidosis treated with high cut-off hemodialysis (HCO-HD) combined with chemotherapy.
- Trial name
- DIACAL (NCT01531751)
- Testing
- High Cut-off Hemodialysis, Chemotherapy
- Where
- Italy
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Head and Neck Cancer, Radiation Toxicity
Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy delivers thin beams of radiation of different strengths directly to the tumor from many angles.
- Conditions
- Head and Neck Cancer, Radiation Toxicity, Xerostomia
- Trial name
- NCT00081029
- Testing
- management of therapy complications, radiation therapy
- Where
- 9 sites in United Kingdom
- Volunteers
- 84 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Smoking Cessation, Smoking Reduction
Preoperative Smoking Cessation in Patients Undergoing Surgery
Background: At present, effectively implementing smoking cessation programs in the health care system constitutes a major challenge. A unique opportunity to initiate smoking cessation focuses on smokers scheduled for surgery.
- Conditions
- Smoking Cessation, Smoking Reduction, Surgery--Complications, Surgery
- Trial name
- PORTICO (NCT05192837)
- Testing
- Intensive preoperative smoking cessation counselling
- Where
- Switzerland
- Volunteers
- 251 people
- Sponsor
- Luzerner Kantonsspital
Myelodysplastic Syndromes,Acute Myeloid Leukemia
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC
evaluate the clinical efficacy and safety of azacitidine combined with HAG regimen for patients with int/high -risk MDS and AML-MRC with less than 30% blasts compared with azacitidine
- Trial name
- NCT03978364
- Testing
- Azacitidine combined HHT, Azacitidine regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shandong Provincial Hospital
Melanoma
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
A novel infrared imaging tool to aid in the clinical detection of atypical pigmented lesions and melanoma is developed. Goals include evaluation of the utility of high-resolution infrared scanning of cutaneous lesions in the…
- Trial name
- NCT01118832
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Amyloid, Cardiac Amyloidosis
Amyloidosis Incidence in High-Risk Cardiac Device Patients
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation.
- Conditions
- Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis
- Trial name
- NCT06186167
- Testing
- Chest Wall Fat Tissue Collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Midwest Heart & Vascular Specialists
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.